[1]郑珂,王勃,赵明.血清PTX3急性肺栓塞患者并发肺动脉压的相关性研究对预后的评估价值[J].心血管病学进展,2020,(12):1328-1332.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.024]
　ZHENG Ke,WANG Bo,ZHAO Ming.Study on the Correlation of Serum PTX3 with Pulmonary Hypertension in Patients with Wcute Pulmonary Embolism and Its Prognostic Value[J].Advances in Cardiovascular Diseases,2020,(12):1328-1332.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.024]
点击复制

血清PTX3急性肺栓塞患者并发肺动脉压的相关性研究对预后的评估价值()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年12期
页码:
1328-1332
栏目:
论著
出版日期:
2020-12-25

文章信息/Info

Title:
Study on the Correlation of Serum PTX3 with Pulmonary Hypertension in Patients with Wcute Pulmonary Embolism and Its Prognostic Value
作者:
郑珂1; 王勃2; 赵明3
(1. 辽宁中医药大学附属第四医院心病科,辽宁 沈阳 110000;2. 31696部队全科,辽宁 沈阳 110000;3. 辽宁中医药大学附属第四医院急诊科,辽宁 沈阳11000)
Author(s):
ZHENG Ke1;  WANG Bo2;  ZHAO Ming3
(1. Department of Cardiology, The Fourth Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110000,Liaoning; 2. General Department of 31696 Army, Shenyang 110000,Liaoning; 3. Department of Emergency, The Fourth Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110000, Liaoning)
关键词:
急性肺栓塞; 肺动脉高压; 正五聚蛋白3; 脑钠肽; 心脏型脂肪酸结合蛋白
Keywords:
Acute pulmonary embolism;  Pulmonary hypertension;  Normal pentapolymerin 3;  Brain natriuretic peptide;  Heart-type fatty acid binding protein
DOI:
10.16806/j.cnki.issn.1004-3934.2020.12.024
摘要:
目的 分析血清正五聚蛋白3（PTX3）水平急性肺栓塞（APE）患者并发肺动脉压（PAH）的相关性其对预后的评估价值。方法 回顾性收集2017年9月2019年9月院呼吸内科收治的83例APE患者的病例资料，以未并发PAH的患者作为非PAH组（n=47），并发PAH的患者作为PAH组（n=36）。比较两组危险分级情况，比较两组不同危险分级患者血清脑钠肽（BNP）、心脏脂肪酸结合蛋白（H-FABP）、D-二聚体（D-D）和PTX3水平，分析PTX3水平BNP、H-FABP、D-D的相关性和BNP、H-FABP、D-D、PTX3水平患者预后的关系，并采用多因素logistic回归分析APE患者并发PAH的危险因素。结果 PAH组血清BNP、H-FABP、D-D和PTX3水平均显著于非PAH组（P0.05）。PAH组中等风险和高风险比例显著于非PAH组，风险比例显著于非PAH组（P0.05）。不同风险分级患者血清BNP、H-FABP、D-DPTX3水平比较，风险患者于中等风险，中等风险患者于风险患者（P0.05）。PAH组、非PAH组和两组合并分析血清PTX3水平BNP、H-FABP、D-D水平均呈显著正相关性（PAH组r分别为0.786、0.728和0.645，非PAH组r分别为0.659、0.704和0.586，两组合并r分别为0.734、0.715和0.619，P0.05）。死亡病例的BNP、H-FABP、D-DPTX3水平显著于存活病例（P0.05）。多因素logistic回归分析结果显示，年龄大，PTX3、BNP、H-FABP和D-dimer水平增是APE患者并发PAH的危险因素，具有统计学意义（OR分别为1.445、1.026、1.158、1.186和1.516，P0.05）。结论 急性肺栓塞肺动脉压（APE-PAH）患者心功能、肺功能损伤程度于APE患者，同时APE患者危险分级越，血清BNP、H-FABP、D-D和PTX3水平越，而PTX3水平BNP、H-FABP和D-D水平呈显著正相关，可作为评估APE-PAH患者预后的指标，同时APE患者并发PAH的危险因素为年龄大，PTX3、BNP、H-FABP和D-dimer水平增。
Abstract:
Objective To analyze the correlation of serum PTX3 level with pulmonary hypertension (PAH) in patients with acute pulmonary embolism (APE) and its prognostic value. Methods Data of 83 cases with APE admitted to department of respiratory medicine in our hospital from September 2017 to September 2019 were retrospectively collected. Patients without PAH were classified into non-PAH group (n=47) and with PAH into PAH group (n=36). Risk grades levels of serum brain natriuretic peptide (BNP), heart-type fatty acid-binding protein (H-FABP), D-Dimer (D-D) and PTX3 were compared. The correlation of PTX3 level with BNP, H-FABP, D-D and relationships of BNP, H-FABP, D-D, PTX3 levels with prognosis were analyzed. Risk factors for PAH in APE patients were investigated by multivariate logistic regression. Results The levels of serum BNP, H-FABP, D-D and PTX3 in PAH group were significantly higher than those in the non-PAH group (P＜0.05). The proportion of medium and high risk was increased with low risk decreased in the PAH group than the non-PAH(P＜0.05). The BNP, H-FABP, D-D and PTX3 levels were elevated in patients with high risk than medium risk,accompanied by the same situation in patients with medium risk than low risk(P＜0.05). The level of serum PTX3 was positively correlated with BNP,H-FABP and D-D in PAH, non-PAH and combined-analysis group (in PAH r=0.786, 0.728 and 0.645, in non-PAH, r=0.659, 0.704 and 0.586, in combined-analysis group r=0.734, 0.715 and 0.619, P＜0.05). The levels of BNP, H-FABP, D-D and PTX3 in death cases were increased than those in survivors (P＜0.05). Results of multivariate logistic regression analysis showed that advanced age,high levels of PTX3, BNP, H-FABP and D-D were risk factors for PAH in APE patients (OR=1.445, 1.026, 1.158, 1.186, 1.516, P＜0.05). Conclusion The degree of cardio-pulmonary functional impairment in APE-PAH patients was higher than that in APE. Meanwhile,serum BNP, H-FABP, D-D and PTX3 levels were increased along with elevated risk grades. The level of PTX3 was positively correlated with BNP, H-FABP and D-D, which could be a biomarker to evaluate prognosis of APE-PAH. The risk factors for PAH in APE patients are advanced age,high levels of PTX3, BNP, H-FABP and D-D.

参考文献/References:

[1].Aleva FEVoets L, Simons SO, et al. Prevalence and localization of pulmonary embolism in unexplained acute exacerbations of COPD: a systematic review and meta-analysis[J]. Chest, 2017, 151(3): 544-554..
[2].Rhodes CJ, Wharton J, Ghataorhe P, et al. Plasma proteome analysis in patients with pulmonary arterial hypertension:an observational cohort study[J]. Lancet Respir Med, 2017, 5(9): 717-726.
[3].Yuichi T, Tomohiko O, Masataka K, et al. Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension[J]. PloS One, 2016, 7(9): 45834.
[4].Sade LE. Acute Pulmonary Embolism Diagnosis and Treatment Guidelines (ESC 2014)[J]. Turk Kardiyol Dern Ars, 2015, 43(1): 7-11.
[5].荆志成徐希奇. 肺动脉压现代分类和诊断策略[J]. 中华心血管病杂志2004, 1(12): 109-111.
[6].Klok FA, Barco S. Follow-up after acute pulmonary embolism[J]. Hamostaseologie, 2018, 38(1): 22-32.
[7].Danzi GB, Loffi M, Galeazzi G, et al. Acute pulmonary embolism and COVID-19 pneumonia:a random association?[J]. Eur Heart J, 2020, 41(19): 1858.
[8].Becattini C, Agnelli G. Risk stratification and management of acute pulmonary embolism[J]. Hematology Am Soc Hematol Educ Program, 2016, 2016(1): 404-412.
[9].Yang H, Zhang J, Huan Y, et al. Pentraxin-3 levels relate to the wells score and prognosis in patients with acute pulmonary embolism[J]. Dis Markers, 2019, 2019(1): 2324515.
[10].Hillbrand M, Spitz RT, Foster HG, et al. Creatine kinase elevations and aggressive behavior in hospitalized forensic patients[J]. Psychiatr Q, 1998, 69(1): 69-82.
[11].Javed QA, Sista AK. Endovascular therapy for acute severe pulmonary embolism[J]. Int J Cardiovasc Imaging, 2019, 35(8): 1443-1452.
[12].Hepburn-Brown M, Darvall J, Hammerschlag G. Acute pulmonary embolism:a concise review of diagnosis and management[J]. Intern Med J, 2019, 49(1): 15-27.
[13].Telo S, Kuluozturk M, Deveci F, et al. The relationship between platelet-to-lymphocyte ratio and pulmonary embolism severity in acute pulmonary embolism[J]. Int Angiol, 2019, 38(1): 4-9.
[14].Dellas C, Lobo JL, Rivas A, et al. Risk stratification of acute pulmonary embolism based on clinical parameters,H-FABP and multidetector CT[J]. Int J Cardiol, 2018, 265(6): 223-228.
[15].Qian HY, Huang J, Yang Y J, et al. Heart-type fatty acid binding protein in the assessment of acute pulmonary embolism[J]. Am J Med Sci, 2016, 352(6): 557-562.

相似文献/References:

[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
　MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(12):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
　ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(12):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
　WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(12):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
　WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(12):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[5]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
　DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(12):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[6]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
　ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(12):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[7]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
　ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(12):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[8]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
　HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(12):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
[9]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
　LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(12):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[10]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
　Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(12):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]

备注/Memo

备注/Memo:
基金项目：辽宁省自然科学基金项目(2014020158)
通信作者：郑珂，E-mail: zhengkesanpu123@163.com
收稿时间：2020-06-15
更新日期/Last Update: 2021-02-22